Shares of Smith & Nephew plc (LON:SN) have been given an average rating of “Hold” by the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is GBX 1,602.86 ($20.94).
A number of analysts have issued reports on SN shares. Credit Suisse Group reaffirmed a “neutral” rating on shares of Smith & Nephew in a research note on Thursday, April 25th. UBS Group raised their target price on Smith & Nephew from GBX 1,730 ($22.61) to GBX 1,830 ($23.91) and gave the stock a “neutral” rating in a research note on Tuesday, August 6th. Berenberg Bank reaffirmed a “hold” rating and issued a GBX 1,475 ($19.27) target price on shares of Smith & Nephew in a research note on Friday, April 26th. JPMorgan Chase & Co. raised their target price on Smith & Nephew from GBX 1,689 ($22.07) to GBX 1,758 ($22.97) and gave the stock a “neutral” rating in a research note on Thursday, May 9th. Finally, Shore Capital reaffirmed a “sell” rating on shares of Smith & Nephew in a research note on Wednesday, July 31st.
Shares of SN traded up GBX 17.50 ($0.23) during midday trading on Friday, reaching GBX 1,897.50 ($24.79). The company had a trading volume of 2,651,108 shares, compared to its average volume of 3,250,000. Smith & Nephew has a 1-year low of GBX 1,242.50 ($16.24) and a 1-year high of GBX 1,940 ($25.35). The stock has a market cap of $16.60 billion and a PE ratio of 23.81. The firm has a 50 day simple moving average of GBX 1,792.53 and a 200-day simple moving average of GBX 1,608.11. The company has a quick ratio of 0.96, a current ratio of 2.00 and a debt-to-equity ratio of 44.00.
About Smith & Nephew
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Featured Story: Why is Cost of Capital Important?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.